All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, Why could mass spectrometry substitute immunofixation electrophoresis (IFE) in diagnosis and monitoring of MM?
Why could mass spectrometry substitute IFE in diagnosis and monitoring of MM?
Paiva describes the benefits of mass spectrometry over IFE, including improved sensitivity, specificity, and prevention of monoclonal antibody interference. He then analyzes the potential for synergy across different imaging techniques when predicting and measuring patient outcomes.
How significant is the role of MRD status in MM, and how can we best utilize this information?
At ASH 2019, Bruno Paiva, University of Navarra, Pamplona, ES, answers the question: How significant is the role of minimal residual disease status in...
How should we monitor risk of progression in patients achieving MRD negativity after auto-SCT?
The Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES, about the importance of monitoring measurable residual disease (MRD)...
Subscribe to get the best content related to multiple myeloma delivered to your inbox